logo
Sarepta Therapeutics: Why Is SRPT Stock Crashing?

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

Forbes3 days ago
CANADA - 2025/06/08: In this photo illustration, the Sarepta Therapeutics logo is seen displayed on ... More a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)
Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlighted the company's apparent undervaluation following its restructuring, its defiant stance has now triggered fresh investor concerns, validating the regulatory risks associated with biotech stocks.
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns. With Elevidys generating 43% of Sarepta's total revenues and holding traditional approval since June 2024 for ambulatory patients, any regulatory challenge poses existential threats to the company.
FDA Commissioner Marty Makary's statement that he's "taking a hard look" at whether Elevidys should remain on the market suggests potential forced withdrawal if voluntary compliance fails. The recent $400 million restructuring cost savings appear insufficient against potential revenue loss from broader market restrictions.
Sarepta's confrontational approach toward federal regulators is creating unprecedented uncertainty, even for biotech investors who typically have a high tolerance for risk. This unwillingness to proactively address safety concerns demonstrates poor risk management, especially at a time when regulatory goodwill is crucial. Situations like this underscore our consistent message about the inherent risks of investing in single stocks and highlight why professionally managed portfolios are often a better choice.
In fact, regulatory risk is just a small part of the risk assessment framework we apply while constructing the Trefis High Quality (HQ) Portfolio which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies

Yahoo

time22 minutes ago

  • Yahoo

Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies

(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases. Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals. The company will lead the research and drug development process, using the funding from Novartis. If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration. Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Here's Laughing Water Capital's Comment on Its New Investment in Clarus Corp. (CLAR)
Here's Laughing Water Capital's Comment on Its New Investment in Clarus Corp. (CLAR)

Yahoo

time22 minutes ago

  • Yahoo

Here's Laughing Water Capital's Comment on Its New Investment in Clarus Corp. (CLAR)

Laughing Water Capital, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter of 2025, Class A interests in Laughing Water Capital returned approximately 13.1% net of all expenses. The SP500TR and R2000 returned 10.9% and 8.5%, respectively. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its second quarter 2025 investor letter, Laughing Water Capital highlighted stocks such as Clarus Corporation (NASDAQ:CLAR). Clarus Corporation (NASDAQ:CLAR) develops and manufactures outdoor equipment and lifestyle products. The one-month return of Clarus Corporation (NASDAQ:CLAR) was 12.71%, and its shares lost 34.05% of their value over the last 52 weeks. On July 23, 2025, Clarus Corporation (NASDAQ:CLAR) stock closed at $3.99 per share, with a market capitalization of $153.223 million. Laughing Water Capital stated the following regarding Clarus Corporation (NASDAQ:CLAR) in its second quarter 2025 investor letter: "Clarus Corporation (NASDAQ:CLAR) – Clarus is a consumer products business focused on outdoor adventure gear. Their Outdoor segment is best known for Black Diamond climbing gear, and their Adventure segment is best known for Rhino-Rack roof racks. Clarus is subscale and undergoing a reset after expanding their SKU count a bit too much. The lack of scale and previous lack of focus leads to GAAP financials that are not pretty; the company struggles with profitability. A hiker in a forest with a backpack of outdoor equipment highlighting the company's lifestyle products. Clarus Corporation (NASDAQ:CLAR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 13 hedge fund portfolios held Clarus Corporation (NASDAQ:CLAR) at the end of the first quarter, which was 13 in the previous quarter. Clarus Corporation's (NASDAQ:CLAR) first quarter sales declined 13% year-over-year to $60.4 million. While we acknowledge the potential of Clarus Corporation (NASDAQ:CLAR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Clarus Corporation (NASDAQ:CLAR) and shared the list of most undervalued stocks with smart money ratings. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.

Lactalis exits Canada plant-based drinks with factory closure
Lactalis exits Canada plant-based drinks with factory closure

Yahoo

time22 minutes ago

  • Yahoo

Lactalis exits Canada plant-based drinks with factory closure

Lactalis has decided to close its plant-based drinks site in Canada. The closure of the facility in Sudbury in Ontario will take effect on 12 December, marking the French dairy giant's 'full exit' from the plant-based drinks market in Canada.. Lactalis said maintaining the plant-based operations is not "financially viable" and does not represent a "sustainable business". The company had been selling plant-based drinks in Canada under the brand Enjoy. Lactalis only launched the brand last year, rolling out a six-strong line of plant-based 'high protein' drinks. However, Lactalis cited a "shift" in market dynamics and the "challenges" posed by the current economic environment as the reasons behind the closure of the Sudbury site. These factors have contributed to a "sustained decline" in the performance of the plant-based beverage category in Canada, it said. 'We are incredibly grateful to our employees in Sudbury for their dedication and contributions over the years. We also extend our sincere thanks to the city of Sudbury for its longstanding partnership and support throughout our time in the community.' Lactalis markets a variety of cheese and milk products under several brands in Canada. The brands it sells in the country include P'tit Québec, Beatrice and Lactantia. Just Drinks asked Lactalis how many jobs would be affected by the closure but the company had not commented at the time of publication. "Lactalis exits Canada plant-based drinks with factory closure" was originally created and published by Just Drinks, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store